



The effects of menstrual cycle on cardiac conduction system

Mehmet Doğan¹, Yaşam Kemal Akpak², Ömer Yiğiner^{3*}

The Effects of Menstrual Cycle on Cardiac Conduction System

Women's cardiac conduction system shows some physiological differences compared to men's. Resting heart rate is higher and QT and corrected QT (QTc) intervals are longer in women. Additionally, female gender is an independent risk factor for drug-related torsades de pointes and congenital long QT syndrome (1). Sudden cardiac death incidence is higher in women when excluding coronary artery disease and structural heart diseases (2). QT interval defines the duration from the beginning of the QRS complex until the end of the T wave and refers to the period of ventricular myocardium activation and repolarization. It may vary according to age, gender, pregnancy condition and the heart rate (3). QT prolongation and shortening may reflect some pathological conditions. QT prolongation occurs in ischemic heart disease, cardiomyopathy, mitral valve prolapse and the use of certain anti-arrhythmic drugs. QT shortening is seen in patients with hypercalcemia and under digitalis treatment. Prolongation of the QT interval can lead to fatal arrhythmias such as ventricular tachycardia and ventricular fibrillation.

Longer QT interval is seen with puberty and recovers after menopause (4,5). These data suggest that, sex hormones may be effective on the QT interval and other repolarization parameters. Additionally some studies showed that, autonomic blockade with atropin and propranolol did not alter intersexual QT interval differences thus supports the relationship between sex hormones and ventricular repolarization disparity (6). During the menstrual cycle, estradiol levels start to rise with follicular phase and remains high until the ovulation. After ovulation, estradiol levels decrease and progesterone levels become higher in the luteal phase. Estradiol and progesterone have opposite effects on cardiac conduction system. Biological effects of estrogen occur by alpha and beta estrogen receptors. These receptors are located at cardiac myocytes, fibroblasts and endothelial cells (7,8). Estrogen receptors are located both in the cytosol and nuclear compartment. While effects of estrogen on the nuclear receptors (called genomic effects) may occur during the hours-days, effects on cytosolic receptors (non-genomic effects) may be seen in seconds. Estrogen has negative inotropic effect on heart

(9). This effect occurs via voltage dependent L-type calcium channel inhibition and decrease of inward calcium flux. Moreover, estrogen exhibits calcium antagonist effect by affecting $\text{Na}^+/\text{Ca}^{2+}$ exchange (10). Additionally, estrogen suppresses the activity of T-type calcium currents, which is important for pacemaker activity, thus leads to negative

chronotropic effects (11,12). While some studies have shown that estrogen decreases potassium channel flow in the third phase of the action potential so causes to QT prolongation (13), some suggest that there is no effect on cardiac repolarization (14). Progesterone is a 21-carbon steroid and produced by corpus luteum, placenta and a small amount of follicles. Its concentrations are high during the luteal phase. Progesterone receptors are located at vascular smooth muscle cells, endothelial cells cardiac myocytes and left atrial appendage myocytes (15-17). Although we have limited data on the effect of progesterone on cardiovascular system, it is thought that progesterone has the opposite effects of estrogen. QT interval is shorter during the luteal phase when progesterone level is high (18,19). Progesterone increases the slowly activated late rectifier potassium current and inhibits L-type calcium channel currents (20). These effects explains why the action potential duration is shorter during luteal phase. Furthermore, these mechanisms reveal the reason of QT interval shortening effects.

The study results of QT interval changes during the menstrual cycle are conflicting. In general, it can be said that QT interval does not change during the menstrual cycle (14,19), some studies have shown that QT interval shortens during luteal phase with high progesterone levels (18). In addition, in case of exposure to QT prolonging drug, QT prolongation was shown to be greater in ovulatory phase than in luteal phase (19). Progesterone and progesterone/estradiol ratio is inversely proportional with the drug associated QT prolongation, that suggests a protec-

Omer Yiginer was born on December 14, 1970 in Ankara, Turkey. He became a medical doctor in 1994 and cardiology specialist in 2001. He has been working since 2008 as an associated professor in the division of cardiology of Gulhane Military Medical Academy, Haydarpasa Hospital, Turkey. He has been working as an interventional cardiologist. Additionally, as a researcher, he is interested in the effects of sexual hormones on cardiac action potential.



Received 10 October 2015, Accepted 2 January 2016, Available online 1 April 2016

¹Ankara Mevki Military Hospital, Department of Cardiology, Ankara, Turkey. ²Ankara Mevki Military Hospital, Department of Obstetrics and Gynaecology, Ankara, Turkey. ³GATA Haydarpaşa Training Hospital, Department of Cardiology, Istanbul, Turkey.

*Corresponding author: Ömer Yiğiner, Tel: +90 533 4876138, Fax: +90 312 2220583, Email: yasamaster@gmail.com

tive role of progesterone (19,21,22). These studies support that estrogen prolongs the QT interval and progesterone shortens.

Ventricular Arrhythmias and Sudden Cardiac Death

Women are less prone to ventricular arrhythmias except torsades de pointes and drug-related ventricular arrhythmias. Sudden cardiac death is defined as death within one hour of symptom onset without any reason, and it is rare in women (23). The reason is not known exactly but lower prevalence of coronary artery disease or less susceptibility to ventricular arrhythmias may be resulted to these gender differences. Ventricular tachycardia (VT) or ventricular fibrillation (VF) is less common in women even if similar ejection fraction, the number of coronary artery disease and myocardial infarction history cases (24). Less VT/VF experience have been identified in women patients with coronary artery disease with implantable cardioverter defibrillator (25).

Animal models suggest that estrogen has protective effects against ventricular arrhythmias. Post-infarction ventricular arrhythmias are less common in rats treated with estrogen (26). Additionally, acute estrogen administration to female rats has revealed protective effects on ischemia related ventricular arrhythmias by calcium channel blocking (27). Furthermore, estrogen administration to dogs of both sexes has been shown to reduce reperfusion related arrhythmias, via nitric oxide release and opening of calcium-activated potassium channels (28).

Some studies have shown that QT interval changes occur during the menstrual cycle and this fluctuations may lead to the risk of arrhythmias in different menstrual phases (29). Nakagawa et al suggested that QT interval is approximately 10 milliseconds shorter in luteal phase and this is the result of progesterone dominance in contrast to estrogen's QT prolonging effect (18). In contrast, some studies showed that there is no significant changes in QT interval with the menstrual cycle (6,14,19). This mismatch in these studies may be due to collected data of patients was not enough to be responsive to individual differences in QT interval and may be unable to sufficiently take into account the biological variables. More comprehensive studies are needed to clarify the effects of sex hormones on cardiac conduction system.

Acknowledgments

None.

Conflict of Interests

The authors declare that they have no conflict of interest. We certify that we had no relationship with companies that may have a financial interest.

References

1. Gowd BM, Thompson PD. Effect of female sex on cardiac arrhythmias. *Cardiol Rev.* 2012;20(6):297-303. doi: 10.1097/CRD.0b013e318259294b.
2. Sedlak T, Shufelt C, Iribarren C, Merz CN. Sex

- hormones and the QT interval: a review. *J Womens Health (Larchmt).* 2012;21(9):933-941.
3. Yıldırım E, Çelik M, Akpak YK. Mitral Stenosis and Pregnancy. *Open Science Journal of Clinical Medicine.* 2015;3(6):220-223.
4. Rautaharju PM, Zhou SH, Wong S, Calhoun HP, Berenson GS, Prineas R, et al. Sex differences in the evolution of the electrocardiographic QT interval with age. *Can J Cardiol.* 1992;8(7):690-695.
5. Furukawa T, Kurokawa J. Regulation of cardiac ion channels via non-genomic action of sex steroid hormones: implication for the gender difference in cardiac arrhythmias. *Pharmacol Ther.* 2007;115(1):106-115. doi:10.1016/j.pharmthera.2007.04.008.
6. Burke JH, Ehlert FA, Kruse JT, Parker MA, Goldberger JJ, Kadish AH. Gender-specific differences in the QT interval and the effect of autonomic tone and menstrual cycle in healthy adults. *Am J Cardiol.* 1997;79(2):178-181. doi:10.1016/s0002-9149(96)00707-2.
7. Meyer R, Linz KW, Surges R, et al. Rapid modulation of L-type calcium current by acutely applied oestrogens in isolated cardiac myocytes from human, guinea-pig and rat. *Exp Physiol.* 1998;83(3):305-321.
8. Grohe C, Kahlert S, Lobbert K, et al. Cardiac myocytes and fibroblasts contain functional estrogen receptors. *FEBS Lett.* 1997;416(1):107-112. doi:10.1113/expphysiol.1998.sp004115. doi:10.1016/s0014-5793(97)01179-4.
9. Sitzler G, Lenz O, Kilter H, La Rosee K, Bohm M. Investigation of the negative inotropic effects of 17 beta-oestradiol in human isolated myocardial tissues. *Br J Pharmacol.* 1996;119(1):43-48. doi:10.1111/j.1476-5381.1996.tb15675.x.
10. Jiang C, Poole-Wilson PA, Sarrel PM, Mochizuki S, Collins P, MacLeod KT. Effect of 17 beta-oestradiol on contraction, Ca²⁺ current and intracellular free Ca²⁺ in guinea-pig isolated cardiac myocytes. *Br J Pharmacol.* 1992;106(3):739-745. doi:10.1111/j.1476-5381.1992.tb14403.x.
11. Eckstein N, Nadler E, Barnea O, Shavit G, Ayalon D. Acute effects of 17 beta-estradiol on the rat heart. *Am J Obstet Gynecol.* 1994;171(3):844-848.
12. Marni F, Wang Y, Morishima M, et al. 17 beta-estradiol modulates expression of low-voltage-activated Ca(V)3.2 T-type calcium channel via extracellularly regulated kinase pathway in cardiomyocytes. *Endocrinology.* 2009;150(2):879-888.
13. Drici MD, Burklow TR, Haridasse V, Glazer RL, Woosley RL. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. *Circulation.* 1996;94(6):1471-1474.
14. Hulot JS, Demolis JL, Riviere R, Strabach S, Christin-Maitre S, Funck-Brentano C. Influence of endogenous oestrogens on QT interval duration. *Eur Heart J.* 2003;24(18):1663-1667.
15. Nakamura Y, Suzuki T, Inoue T, et al. Progesterone receptor subtypes in vascular smooth muscle cells of human aorta. *Endocr J.* 2005;52(2):245-252.

16. Ingegno MD, Money SR, Thelmo W, Greene GL, Davidian M, Jaffe BM, et al. Progesterone receptors in the human heart and great vessels. *Lab Invest.* 1988;59(3):353-356.
17. Knowlton AA, Sun L. Heat-shock factor-1, steroid hormones, and regulation of heat-shock protein expression in the heart. *Am J Physiol Heart Circ Physiol.* 2001;280(1):H455-464.
18. Nakagawa M, Ooie T, Takahashi N, et al. Influence of menstrual cycle on QT interval dynamics. *Pacing Clin Electrophysiol.* 2006;29(6):607-613. doi:10.1111/j.1540-8159.2006.00407.x.
19. Rodriguez I, Kilborn MJ, Liu XK, Pezzullo JC, Woosley RL. Drug-induced QT prolongation in women during the menstrual cycle. *JAMA.* 2001;285(10):1322-1326. doi:10.1016/s1062-1458(01)00329-4.
20. Nakamura H, Kurokawa J, Bai CX, et al. Progesterone regulates cardiac repolarization through a nongenomic pathway: an in vitro patch-clamp and computational modeling study. *Circulation.* 2007;116(25):2913-2922. doi:10.1161/circulationaha.107.702407.
21. Jonsson MK, Vos MA, Duker G, Demolombe S, van Veen TA. Gender disparity in cardiac electrophysiology: implications for cardiac safety pharmacology. *Pharmacol Ther.* 2010;127(1):9-18. doi:10.1016/j.pharmthera.2010.04.002.
22. Cheng J. Evidences of the gender-related differences in cardiac repolarization and the underlying mechanisms in different animal species and human. *Fundam Clin Pharmacol.* 2006;20(1):1-8. doi:10.1111/j.1472-8206.2005.00384.x
23. Kannel WB, Wilson PW, D'Agostino RB, Cobb J. Sudden coronary death in women. *Am Heart J.* 1998;136(2):205-212. doi:10.1053/hj.1998.v136.90226.
24. Vaitkus PT, Kindwall KE, Miller JM, Marchlinski FE, Buxton AE, Josephson ME. Influence of gender on inducibility of ventricular arrhythmias in survivors of cardiac arrest with coronary artery disease. *Am J Cardiol.* 1991;67(6):537-539.
25. Lampert R, McPherson CA, Clancy JF, Caulin-Glaser TL, Rosenfeld LE, Batsford WP. Gender differences in ventricular arrhythmia recurrence in patients with coronary artery disease and implantable cardioverter-defibrillators. *J Am Coll Cardiol.* 2004;43(12):2293-2299. doi:10.1016/j.jacc.2004.03.031.
26. Chen CC, Lin CC, Lee TM. 17 beta-Estradiol decreases vulnerability to ventricular arrhythmias by preserving connexin43 protein in infarcted rats. *Eur J Pharmacol.* 2010;629(1-3):73-81.
27. Philp KL, Hussain M, Byrne NF, Diver MJ, Hart G, Coker SJ. Greater antiarrhythmic activity of acute 17beta-estradiol in female than male anaesthetized rats: correlation with Ca²⁺ channel blockade. *Br J Pharmacol.* 2006;149(3):233-242.
28. Nodé K, Kitakaze M, Sato H, Minamino T, Komamura K, Shinozaki Y, et al. Role of intracellular Ca²⁺ in activation of protein kinase C during ischemic preconditioning. *Circulation.* 1997;96(4):1257-1265.
29. Yang PC, Clancy CE. Effects of sex hormones on cardiac repolarization. *J Cardiovasc Pharmacol.* 2010;56(2):123-129.

Copyright © 2016 The Author(s); This is an open-access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.